Pharos iBio Co., Ltd. (KOSDAQ:388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,120.00
+130.00 (1.86%)
Last updated: Jun 12, 2025
-39.97%
Market Cap 85.70B
Revenue (ttm) n/a
Net Income (ttm) -10.59B
Shares Out 12.95M
EPS (ttm) -818.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,343
Average Volume 48,916
Open 6,980.00
Previous Close 6,990.00
Day's Range 6,950.00 - 7,120.00
52-Week Range 5,300.00 - 12,800.00
Beta n/a
RSI 46.37
Earnings Date Aug 14, 2025

About Pharos iBio

Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-p... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.